Testing ACT201 for chronic hepatitis B
Part of Infections clinical trials.
This trial tests a new medication called ACT201 in two parts: one for healthy volunteers and one for people with chronic hepatitis B. For participants with hepatitis B, the drug may help control the infection, and the study will check its safety and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old (for the hepatitis B part) or 18 to 55 years old (for the healthy volunteer part).
- You have been diagnosed with chronic hepatitis B for at least 6 months (confirmed by positive HBsAg or HBV DNA tests, or a liver biopsy).
- You are currently taking a stable antiviral hepatitis B medication (like tenofovir or entecavir) and will continue it during the study.
- Your liver function tests (ALT) are not more than twice the normal upper limit.
- You are willing to use effective birth control from screening until 6 months after your last study dose and not plan to donate sperm or eggs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This trial tests an investigational drug called IB-001 to see how well it works and how safe it is. It is for healthy volunteers and people with chronic hepatitis B. The goal is to find the best dose and understand side effects.
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This study tests an investigational injection called TVAX-008 for people with chronic hepatitis B. It aims to see if the treatment can help clear the hepatitis B surface antigen, which may lead to a functional cure. The study is for people who have been on antiviral therapy and have well-controlled virus levels.
Hear when a new Chronic Hepaititis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.